Gynecologic Clinical Trials

Meet the experts who make OSUCCC-James a nationally-recognized leader in cancer care and research.

Protocol No.PITitle
OSU-0495Barbara AndersenGynecologic Cancer Survivorship Survey
OSU-10026Barbara AndersenA biobehavioral intervention for patients with gynecologic or breast cancer recurrence
OSU-11160Floor BackesCervical Cancer, Genetic Susceptibility, Biomarkers, and Outcomes
OSU-12114Floor BackesDetection of Sentinel Lymph Nodes in Patients with Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes with Fluorescence Imaging
OSU-13149Floor BackesA Randomized Double-Blind Phase 3 Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer
OSU-08096David CohnChemoFX Observational Study A Non-Interventional, Longitudinal, Multi-Center Initiative Examining Outcomes Associated with the Use of ChemoFX Assay in Solid tumor Malignancies
OSU-0499David CohnTissue, Serum and Data Acquisition Activity for the Study of Gynecologic Disease.
OSU-09008David CohnEvaluation of the Feasibility of Intrauterine Progesterone for the Treatment of Complex Atypical Hyperplasia and Low-grade Endometrial Cancer
OSU-12241David CohnCompassionate Use Protocol : International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen
OSU-13232David CohnCompassionate Use Protocol:ABT-888 FOR A SINGLE PATIENT WITH RECURRENT,PLATINUM RESISTANT OVARIAN CANCER.THE PATIENT HAS BRCA MUTATION.
OSU-13005Brian FochtLifestyle Interventions to Improve Physical Function and Quality of Life in Endometrial Cancer Survivors: The Role of both Aerobic and Yoga based Exercise Programs
OSU-09091Jeffrey FowlerSurgical Staging in the Management of Endometrial Cancer
OSU-05054Kimberly KellySurvey of Cervical and Colorectal Cancer
GOG-0258David O'MalleyA Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
GOG-9923David O'MalleyA Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Agent Bevacizumab [NSC #704865, IND #7921] and CTEP-Supplied Agent ABT-888 [NSC #737664, IND #77840] in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
GOG-0264David O'MalleyA Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG-213David O'MalleyPhase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel in Combination w/ Bevacizumab followed by Bevacizumab & Secondary Cytoreductive Surgery in Platinum-sensitive Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
GOG-0186HDavid O'MalleyA RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN® NSC # 729968, BB-IND # 13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
GOG-0076HHDavid O'MalleyA Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and Ctep Supplied Agent Abt-888 (Velaparib) (Ind#77840, Nsc#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
OSU-13178David O'MalleyA multicenter, observational, prospective study of high-risk first-line and second-line platinum-sensitive ovarian cancer patients
GOG-0238David O'MalleyA Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
GOG-3004David O'MalleyA Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
GOG-0273David O'MalleyChemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
OSU-13214David O'MalleyPhase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer
OSU-13218David O'MalleyRandomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer
GOG-0229ODavid O'MalleyA Randomized Phase II Study with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer
GOG-0275David O'MalleyA PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA
GOG-3003David O'MalleyA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF VTX-2337 (IND #78,416) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
GOG-0274David O'MalleyA Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL
GOG-9927David O'MalleyA PHASE I TRIAL OF DOXIL®, CARBOPLATIN AND NCI SUPPLIED VELIPARIB (ABT-888) IN RECURRENT PLATINUM SENSITIVE OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER
OSU-12038David O'MalleyRandomized Phase II Evaluation of Carboplatinipaclitaxel with and without Trastuzumab (Herceptin®) in Her2/Neu+ Patients with Advancedirecurrent Uterine Serous Papillary Carcinoma
GOG-0244David O'MalleyTHE LYMPHEDEMA AND GYNECOLOGIC CANCER (LEG) STUDY: INCIDENCE, RISK FACTORS, AND IMPACT IN NEWLY DIAGNOSED PATIENTS
GOG-0277David O'MalleyA PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) VERSUS OBSERVATION FOR UTERUS-LIMITED, HIGH-GRADE UTERINE LEIOMYOSARCOMA
OSU-13259David O'MalleyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
GOG-0270David O'MalleyGROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II: An observational study
OSU-13059David O'MalleyA Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors
OSU-13066David O'MalleyThe MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician¿s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
GOG-0269David O'MalleyA Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated with the Surgical Management of a Vulvar Cancer
OSU-13140David O'MalleyA Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
OSU-13148David O'MalleyA Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
OSU-11115Electra PaskettCOMMUNITY AWARENESS, RESOURCES AND EDUCATION (CARE II): PROJECT 4 THE PARENT (PARENTS IN APPALACHIA RECEIVE EDUCATION NEEDED FOR TEENS) PROJECT
OSU-10096Electra PaskettCommunity Awareness, Resources and Education (CARE) II Project 3
OSU-08141Allison QuickMRI-Predictive Assay of Treatment Outcome in Cancer of the Cervix
OSU-13233Paul ReiterFocus Groups to Inform the Development of Interventions to Reduce Cervical Cancer among African American Women
OSU-07014Amanda TolandGenetic Modifiers of Breast and Ovarian Cancer Risk
OSU-10095Christopher WeghorstCommunity Awareness, Resources and Education (CARE II) Project: Project 1

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu